Abstract
SS receptors are overexpressed in many tumors, mainly of neuroendocrine origin, thus enabling the treatment with SS analogs. The clinical experience of receptor radionuclide therapy with the new analog [90Y-DOTA0-Tyr3]-octreotide [90Y-DOTATOC] has been developed over the last decade and is gaining a pivotal role in the therapeutic workout of these tumors. It is well known that some procedures performed in diagnostic and therapeutic management of endocrine tumors, such as agobiopsy and hepatic chemoembolization, can be associated with the occurrence of symptoms related to the release of vasoactive amines and/or hormonal peptides from tumor cell lysis. This is the first report of a severe carcinoid crisis developed after receptor radionuclide therapy with 90Y-DOTATOC administered in a patient affected by liver metastases from bronchial neuroendocrine tumor (atypical carcinoid). Despite protection with H1 receptor antagonists, octreotide and corticosteroids, few days after the therapy the patient complained of persistent flushing of the face and upper trunk, severe labial and periocular oedema, diarrhoea and loss of appetite. These symptoms increased and required new hospitalisation. The patient received iv infusion of octreotide associated with H1 and H2 receptor antagonists and corticosteroid therapy, which induced symptom remission within few days. The case here reported confirms that radionuclide therapy is highly effective in determining early rupture of metastatic tissue and also suggests that pre-medication should be implemented before the radiopeptide administration associated with a close monitoring of the patient in the following days.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999, 11: 858–8.
Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 2003, 12: 231–42.
Kinney MA, Warner ME, Nagorney DM, et al. Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumors. Br J Anaesth 2001, 87: 447–52.
Lamberts SW, Van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996, 334: 246–54
Oberg K, Kvols L, Chaplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol 2004, 15: 966–73.
Garland J, Buscombe JR, Bouvier C, et al. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther 2003, 17: 437–44.
Ricci S, Antonuzzo A, Galli L, et al. Long-acting depot lanreotide in the treatment ofpatients with advanced neuroendocrine tumors. Am J Clin Oncol 2000, 23: 412–5.
Bodei L, Cremonesi M, Grana C, et al. Receptor radionuclide therapy with 90Y-[DOTA]°-Tyr3-octreotide (90Y-DO-TATOC) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging 2004, 7: 1038–46.
De Jong M, Valkema R, Jmar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002, 32: 133–40.
Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002, 43: 610–6.
Kaltas GA, Besser GM, Grossman AB. The diagnosis and management of advanced neuroendocrine tumors. Endocr Rev 2004, 25: 458–511.
Chinol M, Bodei L, Cremonesi M, Paganelli G. Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: The experience of European Institute of Oncology. Sem Nucl Med 2002, 32: 141–7
Paganelli G, Zoboli S, Cremonesi M, et al. Receptor mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. Eur J Nucl Med 2001, 28: 426–34.
Bodei L, Cremonesi M, Zoboli S, et al. Receptor-mediated radionuclide therapy with (90)Y-DOTATOC in association with amino acid infusion: A phase I study. Eur J Nucl Med 2003, 30: 207–16.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Davì, M.V., Bodei, L., Francia, G. et al. Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid). J Endocrinol Invest 29, 563–567 (2006). https://doi.org/10.1007/BF03344149
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03344149